Peter Borchmann
Impact in
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
- Oncology top 0.2%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Papers in
-
- Lymphoma Diagnosis and Treatment 269
- Oncology 132
- CAR-T cell therapy research 66
- Viral-associated cancers and disorders 25
- Co-authors
- Andreas Engert (180 shared papers)Volker Diehl (86 shared papers)Michael Fuchs (116 shared papers)Bastian von Tresckow (78 shared papers)Dennis Alexander Eichenauer (61 shared papers)Boris Böll (45 shared papers)Stephanie Sasse (29 shared papers)Hinrich Peter Hansen (14 shared papers)
- Journals
- Blood (83 papers)Journal of Clinical Oncology (35 papers)HemaSphere (24 papers)Annals of Oncology (16 papers)Hematological Oncology (15 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Peter Borchmann
347 papers receiving 15.5k citations
Peter Borchmann's Hit Papers
Peers
Comparison fields: 5 of 118
- Pathology and Forensic Medicine 8.5k
- Oncology 8.4k
- Neurology 2.5k
- Genetics 1.6k
- Immunology 2.4k
Countries citing papers authored by Peter Borchmann
This map shows the geographic impact of Peter Borchmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Borchmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Borchmann more than expected).
Fields of papers citing papers by Peter Borchmann
This network shows the impact of papers produced by Peter Borchmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Borchmann. The network helps show where Peter Borchmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Borchmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 369 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2018 | 3227 |
| 2 | Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma Hit paper breakdown → | 2010 | 707 |
| 3 | Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy Hit paper breakdown → | 2012 | 577 |
| 4 | Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial Hit paper breakdown → | 2012 | 466 |
| 5 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2021 | 452 |
| 6 | 2010 | 330 | |
| 7 | 2007 | 294 | |
| 8 | 2015 | 281 | |
| 9 | 2017 | 270 | |
| 10 | CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial Hit paper breakdown → | 2023 | 210 |
| 11 | 2012 | 207 | |
| 12 | 2007 | 205 | |
| 13 | 2012 | 194 | |
| 14 | 2012 | 192 | |
| 15 | 2019 | 177 | |
| 16 | 2022 | 175 | |
| 17 | 2005 | 165 | |
| 18 | 2008 | 157 | |
| 19 | 2019 | 156 | |
| 20 | 2013 | 153 |
About Peter Borchmann
Peter Borchmann is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Pulmonary and Respiratory Medicine and Neurology, having authored 369 papers that have together received 15.9k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (269 papers), Lung Cancer Treatments and Mutations (79 papers), CAR-T cell therapy research (66 papers), Chronic Lymphocytic Leukemia Research (50 papers), CNS Lymphoma Diagnosis and Treatment (45 papers), Viral-associated cancers and disorders (25 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Immune Cell Function and Interaction (20 papers). The work is most often cited by research in Pathology and Forensic Medicine (8.5k citations), Oncology (8.4k citations), Neurology (2.5k citations), Genetics (1.6k citations) and Immunology (2.4k citations). Peter Borchmann has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Andreas Engert, Volker Diehl, Michael Fuchs, Bastian von Tresckow, Dennis Alexander Eichenauer, Boris Böll, Stephanie Sasse, Hinrich Peter Hansen, Katrin S. Reiners and Elke Pogge von Strandmann. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Annals of Oncology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.